Annual report
4530.TEDINET S100THNM
Period2023-03-01 → 2024-02-29
Filed2024-05-24
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 158
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥141.7bn | 2023-03-01 → 2024-02-29 | Cons. | Net sales |
| Revenue | ¥128.3bn | 2022-03-01 → 2023-02-28 | Cons. | Net sales |
| Revenue | ¥120.2bn | 2021-03-01 → 2022-02-28d | Cons. | Net sales (5-year summary) |
| Revenue | ¥114.5bn | 2020-03-01 → 2021-02-28d | Cons. | Net sales (5-year summary) |
| Revenue | ¥141.0bn | 2019-03-01 → 2020-02-29d | Cons. | Net sales (5-year summary) |
| Operating income | ¥13.2bn | 2023-03-01 → 2024-02-29 | Cons. | Operating income |
| Operating income | ¥11.6bn | 2022-03-01 → 2023-02-28 | Cons. | Operating income |
| Ordinary income | ¥19.6bn | 2023-03-01 → 2024-02-29 | Cons. | Ordinary income |
| Ordinary income | ¥16.1bn | 2022-03-01 → 2023-02-28 | Cons. | Ordinary income |
| Ordinary income | ¥12.6bn | 2021-03-01 → 2022-02-28d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥11.8bn | 2020-03-01 → 2021-02-28d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥25.6bn | 2019-03-01 → 2020-02-29d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥19.2bn | 2023-03-01 → 2024-02-29 | Cons. | Income before income taxes |
| Profit before tax | ¥16.1bn | 2022-03-01 → 2023-02-28 | Cons. | Income before income taxes |
| Net income (owners) | ¥14.0bn | 2023-03-01 → 2024-02-29 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥11.7bn | 2022-03-01 → 2023-02-28 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥9.7bn | 2021-03-01 → 2022-02-28d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥9.3bn | 2020-03-01 → 2021-02-28d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥18.7bn | 2019-03-01 → 2020-02-29d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥14.4bn | 2023-03-01 → 2024-02-29 | Cons. | Profit loss |
| Net income | ¥12.1bn | 2022-03-01 → 2023-02-28 | Cons. | Profit loss |
| Total assets | ¥328.8bn | at 2024-02-29 | Cons. | Assets |
| Total assets | ¥313.9bn | at 2023-02-28 | Cons. | Assets |
| Total assets | ¥302.9bn | at 2022-02-28d | Cons. | Total assets (5-year summary) |
| Total assets | ¥299.9bn | at 2021-02-28d | Cons. | Total assets (5-year summary) |
| Total assets | ¥307.4bn | at 2020-02-29d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥61.7bn | at 2024-02-29 | Cons. | Liabilities |
| Total liabilities | ¥55.5bn | at 2023-02-28 | Cons. | Liabilities |
| Net assets / equity | ¥267.1bn | at 2024-02-29 | Cons. | Net assets |
| Net assets / equity | ¥258.4bn | at 2023-02-28 | Cons. | Net assets |
| Net assets / equity | ¥254.9bn | at 2022-02-28d | Cons. | Net assets |
| Net assets / equity | ¥253.8bn | at 2021-02-28d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥250.7bn | at 2020-02-29d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥112.5bn | at 2024-02-29 | Cons. | Cash and deposits |
| Cash and deposits | ¥122.2bn | at 2023-02-28 | Cons. | Cash and deposits |
| Cash & equivalents | ¥66.4bn | at 2024-02-29 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥65.4bn | at 2023-02-28 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥86.2bn | at 2022-02-28d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥91.4bn | at 2021-02-28d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥87.0bn | at 2020-02-29d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥18.2bn | 2023-03-01 → 2024-02-29 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥12.7bn | 2022-03-01 → 2023-02-28 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥19.2bn | 2021-03-01 → 2022-02-28d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥5.3bn | 2020-03-01 → 2021-02-28d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥27.4bn | 2019-03-01 → 2020-02-29d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥2.5bn | 2023-03-01 → 2024-02-29 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥23.9bn | 2022-03-01 → 2023-02-28 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥13.1bn | 2021-03-01 → 2022-02-28d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥7.8bn | 2020-03-01 → 2021-02-28d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥17.2bn | 2019-03-01 → 2020-02-29d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥16.7bn | 2023-03-01 → 2024-02-29 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥14.7bn | 2022-03-01 → 2023-02-28 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥15.2bn | 2021-03-01 → 2022-02-28d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥7.2bn | 2020-03-01 → 2021-02-28d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥11.7bn | 2019-03-01 → 2020-02-29d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥181.62 | 2023-03-01 → 2024-02-29 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥148.01 | 2022-03-01 → 2023-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥118.92 | 2021-03-01 → 2022-02-28d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥113.22 | 2020-03-01 → 2021-02-28d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥227.58 | 2019-03-01 → 2020-02-29d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥181.42 | 2023-03-01 → 2024-02-29 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥147.88 | 2022-03-01 → 2023-02-28 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥118.84 | 2021-03-01 → 2022-02-28d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥113.11 | 2020-03-01 → 2021-02-28d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥227.3 | 2019-03-01 → 2020-02-29d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥3,492.62 | at 2024-02-29 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,294.2 | at 2023-02-28 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,171.83 | at 2022-02-28d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,083.98 | at 2021-02-28d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,046.45 | at 2020-02-29d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 80.5% | at 2024-02-29 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 81.6% | at 2023-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.5% | at 2022-02-28d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.1% | at 2021-02-28d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.9% | at 2020-02-29d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 5.4% | 2023-03-01 → 2024-02-29 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.7% | 2022-03-01 → 2023-02-28 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.8% | 2021-03-01 → 2022-02-28d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.7% | 2020-03-01 → 2021-02-28d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.5% | 2019-03-01 → 2020-02-29d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 2,759 | at 2024-02-29 | Cons. | Number of employees |
| Employees | 2,769 | at 2023-02-28 | Cons. | Number of employees |
| Employees | 2,784 | at 2022-02-28d | Cons. | Number of employees |
| Employees | 2,770 | at 2021-02-28d | Cons. | Number of employees |
| Employees | 2,745 | at 2020-02-29d | Cons. | Number of employees |
| Revenue | ¥96.6bn | 2023-03-01 → 2024-02-29 | Standalone | Net sales |
| Revenue | ¥93.0bn | 2022-03-01 → 2023-02-28 | Standalone | Net sales |
| Revenue | ¥90.6bn | 2021-03-01 → 2022-02-28d | Standalone | Net sales (5-year summary) |
| Revenue | ¥86.7bn | 2020-03-01 → 2021-02-28d | Standalone | Net sales (5-year summary) |
| Revenue | ¥109.8bn | 2019-03-01 → 2020-02-29d | Standalone | Net sales (5-year summary) |
| Operating income | ¥10.7bn | 2023-03-01 → 2024-02-29 | Standalone | Operating income |
| Operating income | ¥10.8bn | 2022-03-01 → 2023-02-28 | Standalone | Operating income |
| Ordinary income | ¥14.2bn | 2023-03-01 → 2024-02-29 | Standalone | Ordinary income |
| Ordinary income | ¥14.1bn | 2022-03-01 → 2023-02-28 | Standalone | Ordinary income |
| Ordinary income | ¥10.6bn | 2021-03-01 → 2022-02-28d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥10.4bn | 2020-03-01 → 2021-02-28d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥21.5bn | 2019-03-01 → 2020-02-29d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥13.8bn | 2023-03-01 → 2024-02-29 | Standalone | Income before income taxes |
| Profit before tax | ¥14.2bn | 2022-03-01 → 2023-02-28 | Standalone | Income before income taxes |
| Net income | ¥9.9bn | 2023-03-01 → 2024-02-29 | Standalone | Profit loss |
| Net income | ¥10.4bn | 2022-03-01 → 2023-02-28 | Standalone | Profit loss |
| Net income | ¥7.2bn | 2021-03-01 → 2022-02-28d | Standalone | Net income loss (5-year summary) |
| Net income | ¥8.3bn | 2020-03-01 → 2021-02-28d | Standalone | Net income loss (5-year summary) |
| Net income | ¥15.1bn | 2019-03-01 → 2020-02-29d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥256.0bn | at 2024-02-29 | Standalone | Assets |
| Total assets | ¥254.0bn | at 2023-02-28 | Standalone | Assets |
| Total assets | ¥254.3bn | at 2022-02-28d | Standalone | Total assets (5-year summary) |
| Total assets | ¥264.1bn | at 2021-02-28d | Standalone | Total assets (5-year summary) |
| Total assets | ¥266.1bn | at 2020-02-29d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥43.2bn | at 2024-02-29 | Standalone | Liabilities |
| Total liabilities | ¥39.5bn | at 2023-02-28 | Standalone | Liabilities |
| Net assets / equity | ¥212.8bn | at 2024-02-29 | Standalone | Net assets |
| Net assets / equity | ¥214.5bn | at 2023-02-28 | Standalone | Net assets |
| Net assets / equity | ¥222.4bn | at 2022-02-28d | Standalone | Net assets |
| Net assets / equity | ¥231.2bn | at 2021-02-28d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥225.6bn | at 2020-02-29d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥52.0bn | at 2024-02-29 | Standalone | Cash and deposits |
| Cash and deposits | ¥68.6bn | at 2023-02-28 | Standalone | Cash and deposits |
| EPS (basic) | ¥128.08 | 2023-03-01 → 2024-02-29 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥131.21 | 2022-03-01 → 2023-02-28 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥88.25 | 2021-03-01 → 2022-02-28d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥102.07 | 2020-03-01 → 2021-02-28d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥183.45 | 2019-03-01 → 2020-02-29d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥127.93 | 2023-03-01 → 2024-02-29 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥131.1 | 2022-03-01 → 2023-02-28 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥88.19 | 2021-03-01 → 2022-02-28d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥101.97 | 2020-03-01 → 2021-02-28d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥183.23 | 2019-03-01 → 2020-02-29d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥85 | 2023-03-01 → 2024-02-29 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥84.5 | 2022-03-01 → 2023-02-28 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥84 | 2021-03-01 → 2022-02-28d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥83.5 | 2020-03-01 → 2021-02-28d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥83 | 2019-03-01 → 2020-02-29d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,804.37 | at 2024-02-29 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,754.67 | at 2023-02-28 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,784.39 | at 2022-02-28d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,825.43 | at 2021-02-28d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,755.32 | at 2020-02-29d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 83.0% | at 2024-02-29 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.3% | at 2023-02-28 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.3% | at 2022-02-28d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.5% | at 2021-02-28d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.6% | at 2020-02-29d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 4.6% | 2023-03-01 → 2024-02-29 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.8% | 2022-03-01 → 2023-02-28 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.2% | 2021-03-01 → 2022-02-28d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.7% | 2020-03-01 → 2021-02-28d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.7% | 2019-03-01 → 2020-02-29d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 85,164,895 | at 2024-02-29 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 85,164,895 | at 2023-02-28 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 85,164,895 | at 2022-02-28d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 85,164,895 | at 2021-02-28d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 85,164,895 | at 2020-02-29d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 1,506 | at 2024-02-29 | Standalone | Number of employees |
| Employees | 1,521 | at 2023-02-28 | Standalone | Number of employees |
| Employees | 1,587 | at 2022-02-28d | Standalone | Number of employees |
| Employees | 1,583 | at 2021-02-28d | Standalone | Number of employees |
| Employees | 1,569 | at 2020-02-29d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 2
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2024-02-29 | 58 pure |
| Pharmaceutical Businessreportable segment | employees | at 2024-02-29 | 2701 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,978
| Item | Context | Value | Unit |
|---|---|---|---|
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)医薬品事業の取引先であり、取引関係維持・強化を図るため。取引先持株会を通じた取得による増加。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Original text (Japanese)小野薬品工業㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Original text (Japanese)協力関係の構築により、企業価値向上を図るため。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row4Member | Original text (Japanese)㈱シマノ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row4Member | Original text (Japanese)協力関係の構築により、企業価値向上を図るため。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row4Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Original text (Japanese)日清食品ホールディングス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Original text (Japanese)協力関係の構築により、企業価値向上を図るため。(注)２ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row6Member | Original text (Japanese)㈱大阪ソーダ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row6Member | Original text (Japanese)協力関係の構築により、企業価値向上を図るため。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row6Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row7Member | Original text (Japanese)㈱ヤクルト本社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row7Member | Original text (Japanese)協力関係の構築により、企業価値向上を図るため。(注)３ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row7Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row8Member | Original text (Japanese)セーレン㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row8Member | Original text (Japanese)医薬品事業の取引先であり、取引関係維持・強化を図るため。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row8Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row9Member | Original text (Japanese)三浦工業㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row9Member | Original text (Japanese)医薬品事業の取引先であり、取引関係維持・強化を図るため。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row9Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row10Member | Original text (Japanese)㈱クラレ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row10Member | Original text (Japanese)医薬品事業の取引先であり、取引関係維持・強化を図るため。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row10Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row11Member | Original text (Japanese)エーザイ㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row11Member | Original text (Japanese)協力関係の構築により、企業価値向上を図るため。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row11Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row12Member | Original text (Japanese)㈱オカムラ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row12Member | Original text (Japanese)医薬品事業の取引先であり、取引関係維持・強化を図るため。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row12Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row13Member | Original text (Japanese)大成建設㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row13Member | Original text (Japanese)協力関係の構築により、企業価値向上を図るため。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row13Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row14Member | Original text (Japanese)レンゴー㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row14Member | Original text (Japanese)医薬品事業の取引先であり、取引関係維持・強化を図るため。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row14Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row15Member | Original text (Japanese)日本ゼオン㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row15Member | Original text (Japanese)医薬品事業の取引先であり、取引関係維持・強化を図るため。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row15Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row16Member | Original text (Japanese)ダイダン㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row16Member | Original text (Japanese)協力関係の構築により、企業価値向上を図るため。(注)４ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row16Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row17Member | Original text (Japanese)江崎グリコ㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row17Member | Original text (Japanese)協力関係の構築により、企業価値向上を図るため。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row17Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row18Member | Original text (Japanese)アルフレッサホールディングス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row18Member | Original text (Japanese)医薬品事業の販売先であり、取引関係維持・強化を図るため。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row18Member | Original text (Japanese)有 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |